Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam.

Tomalik-Scharte D, Suleiman AA, Frechen S, Kraus D, Kerkweg U, Rokitta D, Di Gion P, Queckenberg C, Fuhr U.

J Clin Pharmacol. 2014 Oct;54(10):1162-9. doi: 10.1002/jcph.318. Epub 2014 May 5.


A novel toxicokinetic modeling of cypermethrin and permethrin and their metabolites in humans for dose reconstruction from biomarker data.

Côté J, Bonvalot Y, Carrier G, Lapointe C, Fuhr U, Tomalik-Scharte D, Wachall B, Bouchard M.

PLoS One. 2014 Feb 26;9(2):e88517. doi: 10.1371/journal.pone.0088517. eCollection 2014.


Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.

Abduljalil K, Lazar S, Natanzon M, Wu W, Zadoyan G, Steffens B, Kohl V, Mörike K, Tomalik-Scharte D, Stingl J, Schwab M, Harenberg J, Gleiter C, Fuhr U.

Clin Pharmacokinet. 2013 May;52(5):359-71. doi: 10.1007/s40262-013-0043-z.


The role of human cytochrome P450 enzymes in metabolism of acrylamide in vitro.

Kraus D, Rokitta D, Fuhr U, Tomalik-Scharte D.

Toxicol Mech Methods. 2013 Jun;23(5):346-51. doi: 10.3109/15376516.2012.759307. Epub 2013 Jan 28.


Profiling of mercapturic acids of acrolein and acrylamide in human urine after consumption of potato crisps.

Watzek N, Scherbl D, Feld J, Berger F, Doroshyenko O, Fuhr U, Tomalik-Scharte D, Baum M, Eisenbrand G, Richling E.

Mol Nutr Food Res. 2012 Dec;56(12):1825-37. doi: 10.1002/mnfr.201200323. Epub 2012 Oct 27.


Pharmacokinetics, pharmacodynamics, and comparative bioavailability of single, oral 2-mg doses of dexamethasone liquid and tablet formulations: a randomized, controlled, crossover study in healthy adult volunteers.

Queckenberg C, Wachall B, Erlinghagen V, Di Gion P, Tomalik-Scharte D, Tawab M, Gerbeth K, Fuhr U.

Clin Ther. 2011 Nov;33(11):1831-41. doi: 10.1016/j.clinthera.2011.10.006. Epub 2011 Nov 1.


Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.

Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D, Doroshyenko O, Jetter A, Stingl JC.

Drug Metab Dispos. 2011 May;39(5):927-32. doi: 10.1124/dmd.110.036921. Epub 2011 Jan 26.


Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.

Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U.

Clin Pharmacol Ther. 2010 Nov;88(5):643-51. doi: 10.1038/clpt.2010.137. Epub 2010 Sep 29.


Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.

Tomalik-Scharte D, Maiter D, Kirchheiner J, Ivison HE, Fuhr U, Arlt W.

Eur J Endocrinol. 2010 Dec;163(6):919-24. doi: 10.1530/EJE-10-0764. Epub 2010 Sep 15.


Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.

Lindauer A, Di Gion P, Kanefendt F, Tomalik-Scharte D, Kinzig M, Rodamer M, Dodos F, Sörgel F, Fuhr U, Jaehde U.

Clin Pharmacol Ther. 2010 May;87(5):601-8. doi: 10.1038/clpt.2010.20. Epub 2010 Apr 7. Erratum in: Clin Pharmacol Ther. 2010 Oct;88(4):566.


Absorption, pharmacokinetics, and safety of triclosan after dermal administration.

Queckenberg C, Meins J, Wachall B, Doroshyenko O, Tomalik-Scharte D, Bastian B, Abdel-Tawab M, Fuhr U.

Antimicrob Agents Chemother. 2010 Jan;54(1):570-2. doi: 10.1128/AAC.00615-09. Epub 2009 Oct 12.


Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?

Tomalik-Scharte D, Lütjohann D, Doroshyenko O, Frank D, Jetter A, Fuhr U.

Clin Pharmacol Ther. 2009 Aug;86(2):147-53. doi: 10.1038/clpt.2009.72. Epub 2009 May 20.


In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans.

Doroshyenko O, Fuhr U, Kunz D, Frank D, Kinzig M, Jetter A, Reith Y, Lazar A, Taubert D, Kirchheiner J, Baum M, Eisenbrand G, Berger FI, Bertow D, Berkessel A, Sörgel F, Schömig E, Tomalik-Scharte D.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):433-43. doi: 10.1158/1055-9965.EPI-08-0832. Epub 2009 Feb 3.


Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?

Jetter A, Kinzig M, Rodamer M, Tomalik-Scharte D, Sörgel F, Fuhr U.

Eur J Clin Pharmacol. 2009 Apr;65(4):411-7. doi: 10.1007/s00228-008-0597-0. Epub 2008 Dec 13.


No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam.

Tomalik-Scharte D, Doroshyenko O, Kirchheiner J, Jetter A, Lazar A, Klaassen T, Frank D, Wyen C, Fätkenheuer G, Fuhr U.

Eur J Clin Pharmacol. 2008 Oct;64(10):1033-5. doi: 10.1007/s00228-008-0503-9. Epub 2008 Jun 28. No abstract available.


8. Application of Pharmacogenetics in Dose Individualization in Diabetes, Psychiatry, Cancer and Cardiology.

Tomalik-Scharte D.

EJIFCC. 2008 Apr 3;19(1):54-61. eCollection 2008 Apr. No abstract available.


Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity.

Klaassen T, Jetter A, Tomalik-Scharte D, Kasel D, Kirchheiner J, Jaehde U, Fuhr U.

Eur J Clin Pharmacol. 2008 Apr;64(4):387-98. Epub 2007 Dec 11.


The clinical role of genetic polymorphisms in drug-metabolizing enzymes.

Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J.

Pharmacogenomics J. 2008 Feb;8(1):4-15. Epub 2007 Jun 5. Review.


Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.

Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, Jetter A, Stehle S, Tsahuridu M, Meineke I, Brockmöller J, Fuhr U.

Clin Pharmacol Ther. 2006 Dec;80(6):657-67.


Toxicokinetics of acrylamide in humans after ingestion of a defined dose in a test meal to improve risk assessment for acrylamide carcinogenicity.

Fuhr U, Boettcher MI, Kinzig-Schippers M, Weyer A, Jetter A, Lazar A, Taubert D, Tomalik-Scharte D, Pournara P, Jakob V, Harlfinger S, Klaassen T, Berkessel A, Angerer J, Sörgel F, Schömig E.

Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):266-71.


Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers.

Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, Skott A, Sörgel F, Klaassen T, Kasel D, Harlfinger S, Doroshyenko O, Frank D, Kirchheiner J, Bräter M, Richter K, Gramatté T, Fuhr U.

Drug Metab Dispos. 2005 Dec;33(12):1859-66. Epub 2005 Sep 23.


Dermal absorption of permethrin following topical administration.

Tomalik-Scharte D, Lazar A, Meins J, Bastian B, Ihrig M, Wachall B, Jetter A, Tantcheva-Poór I, Mahrle G, Fuhr U.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):399-404. Epub 2005 Jun 10.


Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, Cascorbi I, Doroshyenko O, Sörgel F, Fuhr U.

Antimicrob Agents Chemother. 2005 May;49(5):1733-8.


Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation.

Sörgel F, Fuhr U, Minic M, Siegmund M, Maares J, Jetter A, Kinzig-Schippers M, Tomalik-Scharte D, Szymanski J, Goeser T, Toex U, Scheidel B, Lehmacher W.

Int J Clin Pharmacol Ther. 2005 Mar;43(3):140-9.


Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.

Jetter A, Kinzig-Schippers M, Skott A, Lazar A, Tomalik-Scharte D, Kirchheiner J, Walchner-Bonjean M, Hering U, Jakob V, Rodamer M, Jabrane W, Kasel D, Brockmöller J, Fuhr U, Sörgel F.

Eur J Clin Pharmacol. 2004 May;60(3):165-71. Epub 2004 Mar 25.


Do data presented at an American Society for Clinical Pharmacology and Therapeutics meeting make it to full publication?

Riessland M, Tomalik-Scharte D, Fuhr U.

Clin Pharmacol Ther. 2004 Jan;75(1):123-4. No abstract available.


Supplemental Content

Loading ...
Support Center